News & Blog

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Lexeo Announces FDA Clearance of IND Application for LX2006 for Friedreich’s Ataxia Cardiomyopathy

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

Meet the Community – Richard Brown MBE

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Meet the Community – Shelby Wright

Meet the Community – Christiane Wick-Jüttner

Meet the Community – Ribar Mohamad

Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006

Meet the Community – David (Dave) Arnold